Landmark Study Finds PreTRM® Blood Test Reduces Earliest Preterm Births and Newborn Complications [Yahoo! Finance]
Sera Prognostics, Inc. - Class A (SERA)
Company Research
Source: Yahoo! Finance
SALT LAKE CITY Jan. 7, 2026 /PRNewswire/ -- A randomized controlled trial of 5,018 women has found that a simple blood test, when paired with targeted interventions, can significantly reduce the risk of preterm birth and improve outcomes for newborns. The findings, published in PREGNANCY, the peer-reviewed journal of the Society for Maternal-Fetal Medicine, highlight the effectiveness of the PreTRM Test in identifying women at higher risk for spontaneous preterm birth and guiding preventive care. Key findings from the PRIME Study include: 56% and 32% fewer babies were born before 32 and 35 weeks, respectively 20% fewer babies admitted to the NICU Fewer health complications for newborns (20% reduction in odds of neonatal morbidity) A NICU day was saved for every 4.2 patients screened The PreTRM Test is a first-of-its-kind, personalized, non-invasive blood test that predicts the risk of spontaneous preterm birth in asymptomatic women carrying a single baby. In the study, wo
Show less
Read more
Impact Snapshot
Event Time:
SERA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SERA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SERA alerts
High impacting Sera Prognostics, Inc. - Class A news events
Weekly update
A roundup of the hottest topics
SERA
News
- Hera Women's Health Highlights Sera Prognostics PRIME Trial Results Led by Brian K. Iriye, MD Showing Biomarker-Guided Care Improves Newborn Outcomes and Reduces NICU UsePR Web
- Landmark Study Finds PreTRM® Blood Test Reduces Earliest Preterm Births and Newborn ComplicationsPR Newswire
- With 40% ownership, Sera Prognostics, Inc. (NASDAQ:SERA) has piqued the interest of institutional investors [Yahoo! Finance]Yahoo! Finance
- Sera Prognostics (NASDAQ:SERA) was upgraded by analysts at Jefferies Financial Group Inc. to a "strong-buy" rating.MarketBeat
- Sera Prognostics (NASDAQ:SERA) is now covered by analysts at Jefferies Financial Group Inc.. They set a "buy" rating on the stock.MarketBeat
SERA
Earnings
- 11/13/25 - Beat
SERA
Sec Filings
- 1/16/26 - Form SCHEDULE
- 1/8/26 - Form 8-K
- 1/7/26 - Form 8-K
- SERA's page on the SEC website